Back to Search
Start Over
Piperlongumine promotes death of retinoblastoma cancer cells
- Source :
- Oncotarget
- Publication Year :
- 2021
- Publisher :
- Impact Journals, LLC, 2021.
-
Abstract
- Retinoblastoma is the most common pediatric intraocular malignant tumor. While retinoblastoma initiation is triggered by the inactivation of both alleles of the retinoblastoma tumor suppressor gene (RB1) in the developing retina, tumor progression requires additional epigenetic changes, retinoblastoma genomes being quite stable. Although the management of RB has recently improved, new therapeutic agents are necessary to improve the treatment of advanced forms of retinoblastoma. In this report, we analyzed the pro-death effect of piperlongumine (PL), a natural compound isolated from Piper longum L., on two human retinoblastoma cell lines, WERI-Rb and Y79. The effects of PL on cell proliferation, cell death and cell cycle were investigated. PL effectively inhibited cell growth, impacted the cell cycle by decreasing the level of cyclins and CDK1 and increasing CDKN1A and triggered a caspase-3 independant cell death process in which reactive oxygen species (ROS) production is a major player. Indeed, PL toxicity in retinoblastoma cell lines was inhibited by a ROS scavenger N-acetyl-l-cysteine (NAC) treatment. These findings suggest that PL reduces tumor growth and induces cell death by regulating the cell cycle.
- Subjects :
- 0301 basic medicine
Tumor suppressor gene
piperlongumine
Biology
retinoblastoma
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
medicine
cancer
programmed cell death
Piperlongumine
Retinoblastoma
Cell growth
Cell cycle
medicine.disease
eye diseases
030104 developmental biology
Oncology
chemistry
Tumor progression
Cell Death Process
030220 oncology & carcinogenesis
Cancer cell
Cancer research
Research Paper
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....77310524d2a4de1b3e78119cfe541faa
- Full Text :
- https://doi.org/10.18632/oncotarget.27947